ストックスクリーナーアプリを入手
0.84
2.29%
-0.0197
前日終値:
$0.8597
開ける：
$0.84
24時間の取引高:
36,998
Relative Volume:
0.08
時価総額：
$51.02M
収益：
$2.43M
当期純損益:
$-52.67M
株価収益率:
-0.6667
EPS:
-1.26
ネットキャッシュフロー:
$-33.04M
1週間 パフォーマンス:
+2.44%
1か月 パフォーマンス:
+6.50%
6か月 パフォーマンス:
-0.41%
1年 パフォーマンス:
-42.07%
1日の値動き範囲:
$0.8292
$0.8597
1週間の範囲:
$0.82
$0.9094
52週間の値動き範囲:
$0.6301
$1.58
Lucid Diagnostics Inc Stock (LUCD) Company Profile
LUCD を他の銘柄と比較する
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
LUCD
Lucid Diagnostics Inc
|
0.84 | 51.02M | 2.43M | -52.67M | -33.04M | -1.26 |
|
ABT
Abbott Laboratories
|
112.84 | 196.55B | 41.22B | 5.77B | 6.49B | 3.29 |
|
BSX
Boston Scientific Corp
|
95.70 | 141.03B | 15.91B | 1.79B | 1.89B | 1.21 |
|
SYK
Stryker Corp
|
366.81 | 138.80B | 21.97B | 3.59B | 3.21B | 9.33 |
|
MDT
Medtronic Plc
|
81.54 | 104.60B | 33.00B | 4.29B | 5.50B | 3.27 |
|
EW
Edwards Lifesciences Corp
|
73.32 | 43.73B | 6.60B | 4.16B | 490.10M | 6.93 |
Lucid Diagnostics Inc Stock (LUCD) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2021-12-27 | 開始されました | Ascendiant Capital Markets | Buy |
| 2021-11-08 | 開始されました | BTIG Research | Buy |
| 2021-11-08 | 開始されました | Cantor Fitzgerald | Overweight |
| 2021-11-08 | 開始されました | Needham | Buy |
Lucid Diagnostics Inc (LUCD) 最新ニュース
Lucid Diagnostics to Participate in the 2024 Maxim Healthcare Virtual Summit - Kilgore News Herald
Lucid Inks New Partnership With VITALExam: Stock to Gain? - MSN
Lucid Diagnostics Executes Contract to Provide EsoGuard® Esophag - GuruFocus.com
Lucid Gains Extension of Compliance by NASDAQ - Baystreet.ca
Lucid Diagnostics Granted 180-Day Extension by Nasdaq to Regain Compliance with Minimum Bid Price Rule - Quantisnow
Lucid Diagnostics Granted Extension by Nasdaq to Regain Compliance with Minimum Bid Price Requirement - Defense World
Lucid Diagnostics to Present at the Canaccord Genuity MedTech, Diagnostics and Digital Health & Services Forum - The Eastern Progress Online
Lucid Diagnostics Partners with VITALExam to Screen Firefighters at High Risk of Esophageal Cancer - StockTitan
Lucid Diagnostics Receives Notice of Allowance for Key Patent Underlying Its EsoGuard Esophageal DNA Test - The Eastern Progress Online
Lucid Diagnostics' SWOT analysis: stock faces challenges amid market potential - Investing.com
Prospective Clinical Utility Study of Lucid Diagnostics' EsoGuard® Esophageal DNA Test Accepted for Peer-Reviewed Publication - Morningstar
Prospective Clinical Utility Study of Lucid Diagnostics' EsoGuard® Esophageal DNA Test Accepted for Peer-Reviewed Publication (PR Newswire) - Aktiellt
Lucid Diagnostics' EsoGuard Shows Breakthrough 85% Compliance Rate in Major Clinical Study - StockTitan
Lucid Diagnostics (NASDAQ:LUCD) Price Target Lowered to $7.00 at Ascendiant Capital Markets - Defense World
Lucid Diagnostics Signs Memorandum of Understanding with Front Line Mobile Health - The Eastern Progress Online
Lucid Diagnostics Completes Convertible Debt Refinancing to Strengthen Balance Sheet and Extend Cash Runway Past Key Near-Term Milestones - The Eastern Progress Online
PAVmed Provides Business Update and Third Quarter 2024 Financial Results - The Eastern Progress Online
Lucid Diagnostics Completes Convertible Debt Refinancing to Strengthen Balance Sheet and Extend Cash Runway Past Key Near-Term Milestones – Company AnnouncementFT.com - Financial Times
Lucid Diagnostics Secures $21.95M Convertible Note Financing, Extends Cash Runway - StockTitan
Lucid Diagnostics Inc. (NASDAQ:LUCD) Short Interest Down 30.6% in November - MarketBeat
Lucid Diagnostics’ Strategic Financial Maneuvering and Agreements - TipRanks
Head-To-Head Review: Lucid Diagnostics (NASDAQ:LUCD) & DIH Holding US (NASDAQ:DHAI) - Defense World
This Pill-Size Diagnostic Seeks to Prevent Thousands of Esophageal Cancer Deaths - MedCity News
Lucid Diagnostics to Participate in the 2024 Maxim Healthcare Vi - GuruFocus.com
Lucid Diagnostics Provides Business Update and Third Quarter 202 - GuruFocus.com
Lucid Diagnostics' SWOT analysis: stock outlook amid reimbursement progress - Investing.com
Lucid Diagnostics Submits Clinical Evidence Package to MolDX Seeking Medicare Coverage for EsoGuard® Esophageal DNA Test - Morningstar
Lucid Diagnostics Announces Agreement for Sale of Senior Secured Convertible Notes - Defense World
Lucid Diagnostics Inc. announced that it expects to receive $21.75 million in funding - Marketscreener.com
Lucid Diagnostics to Present at the Canaccord Genuity MedTech, D - GuruFocus.com
Cantor Fitzgerald cuts Lucid Diagnostics stock target, overweight on challenges - Investing.com Australia
LUCDLucid Diagnostics Inc. Latest Stock News & Market Updates - StockTitan
Lucid Diagnostics (NASDAQ:LUCD) Price Target Lowered to $2.00 at Cantor Fitzgerald - MarketBeat
PAVmed Inc. (PAVM) Quarterly 10-Q Report - Quartzy
Lucid Diagnostics (NASDAQ:LUCD) Provides Business Update and Financial Results - Defense World
Lucid Diagnostics' (LUCD) Buy Rating Reiterated at Canaccord Genuity Group - MarketBeat
Needham & Company LLC Reaffirms "Buy" Rating for Lucid Diagnostics (NASDAQ:LUCD) - MarketBeat
PAVmed Inc Reports Q3 2024 Earnings: Revenue at $996,000, Non-GA - GuruFocus.com
Lucid Diagnostics Inc. (NASDAQ:LUCD) Q3 2024 Earnings Call Transcript - Insider Monkey
Earnings call: Lucid Diagnostics reports revenue growth and strategic expansion - Investing.com UK
PAVmed Hits Record $1.2M EsoGuard Revenue in Q3, Up 20% Despite Cash Challenges - StockTitan
Lucid Diagnostics Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2024 - Marketscreener.com
Lucid Diagnostics Inc (LUCD) Q3 2024 Earnings Call Highlights: Record Revenue Growth Amid ... By GuruFocus - Investing.com Canada
Lucid Diagnostics Reports Q3 Revenue Growth and Strategic Expansion - TipRanks
PAVMPAVmed Inc. Latest Stock News & Market Updates - StockTitan
Needham maintains Buy rating on Lucid Diagnostics shares - Investing.com
Needham maintains Buy rating on Lucid Diagnostics shares By Investing.com - Investing.com UK
Lucid Diagnostics Reports Revenue Growth and Secures Funding - TipRanks
Lucid Diagnostics Provides Business Update and Third Quarter 2024 Financial Results - PR Newswire
Lucid Diagnostics Announces Convertible Notes Exchange Initiative - TipRanks
Lucid Diagnostics (LUCD) Scheduled to Post Earnings on Wednesday - MarketBeat
Lucid Diagnostics Inc (LUCD) 財務データ
収益
当期純利益
現金流量
EPS
3.22%
0.63%
大文字化:
|
ボリューム (24 時間):